State Street’s Verona Pharma VRNA Stock Holding History

State Street’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-74,350	Closed	-$7.93M	–	4355
2025 Q3	$7.93M	Buy	74,350 +68,030	+1,076%	+$7.1M	﹤0.01%	2762
2025 Q2	$598K	Buy	+6,320	New	+$468K	﹤0.01%	3586
2024 Q3	–	Sell	-33,572	Closed	-$485K	–	4340
2024 Q2	$485K	Hold	33,572	–	–	﹤0.01%	3569
2024 Q1	$540K	Sell	33,572 -4,788	-12%	-$82.8K	﹤0.01%	3625
2023 Q4	$763K	Hold	38,360	–	–	﹤0.01%	3537
2023 Q3	$625K	Buy	38,360 +20,500	+115%	+$395K	﹤0.01%	3619
2023 Q2	$378K	Sell	17,860 -38,019	-68%	-$811K	﹤0.01%	3772
2023 Q1	$1.12M	Buy	55,879 +44,406	+387%	+$959K	﹤0.01%	3496
2022 Q4	$300K	Sell	11,473 -437,556	-97%	-$5.83M	﹤0.01%	3942
2022 Q3	$4.23M	Buy	+449,029	New	+$3.78M	﹤0.01%	3141

Other funds holding VRNA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

State Street's VRNA Position: Q4 2025 in Review

State Street sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 74,350 shares — an estimated $7.93M sold.

State Street first reported a position in VRNA in Q3 2022 and held it in 10 quarters. The position peaked at $7.93M in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

State Street reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
State Street sold 74,350 Verona Pharma shares in Q4 2025, an estimated $7.93M.
State Street first reported a position in Verona Pharma in Q3 2022 and held it in 10 quarters.
State Street's Verona Pharma position peaked at $7.93M in Q3 2025.
1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on State Street's 13F filing for Q4 2025, filed 13 Feb 2026.